


# 글로벌 제약사 파이프라인 분석

## - Astellas -


2022. 10.  
국가신약개발사업단

• 질환별 파이프라인



질환분야	개수	비중
Oncology	20	57%
Musculoskeletal	3	8.5%
Hematology	2	5.5%
Genitourinary	2	5.5%
Others	2	5.5%
Ophthalmology	1	3%
Neuroscience	1	3%
Endocrine	1	3%
Immunology	1	3%
Infectious	1	3%
Metabolic	1	3%
<b>합계</b>	<b>35개</b>	<b>100%</b>

• 물질별 파이프라인



물질	개수	비중
Small molecules	20	57%
Cell therapy	4	11.5%
ADC	4	11.5%
Antibody	3	8%
Gene Therapy	2	6%
Virus	1	3%
Protein	1	3%
<b>합계</b>	<b>35개</b>	<b>100%</b>

## • 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Endocrine	Phase 3	ESN364		fezolinetant	Menopause, vasomotor symptoms associated	Small molecules	Neurokinin 3 receptor (NK3R)	NK3R antagonist	Mono	-
2	Genitourinary	Phase 3	YM178		mirabegron	Neurogenic detrusor overactivity, pediatrics	Small molecules	Adrenergic receptor beba 3(ADRB3)	ADRB3 agonist	Mono	-
3	Genitourinary	Phase 3	YM178	Myrbetriq	mirabegron	Overactive bladder, pediatrics	Small molecules	Adrenergic receptor beba 3(ADRB3)	ADRB3 agonist	Mono	-
4	Hematology	Phase 2	ASP1517	Evrenzo	roxadustat	Anemia, Chemotherapy-induced	Small molecules	Hypoxia-inducible factor prolyl hydroxylase (HIF-PH)	HIF-PH inhibitor	Mono	FibroGen
5	Hematology	Phase 1	ASP8731			Sickle cell disease	Small molecules	BTB and CNC homology 1(BACH1)	BACH1 inhibitor	Mono	-
6	Immunology	Phase 3	ASP015K		peficitinib	Theumatoid arthritis	Small molecules	JAK	JAK inhibitor	Mono	-
7	Infectious	Phase 2		Cresemba	isavuconazole	Invasive aspergillosis and mucormycosis, pediatrics	Small molecules	14 alpha-sterol Demethylase	Azole antifungal	Mono	Basilea
8	Metabolic	Phase 1	AT845			Pompe disease	Gene therapy	Acid alpha glucosidase(GAA)	AAV-based gene therapy	Mono	-
9	Musculoskeletal	Phase 2	ASP0367		bocidelpar	Mitochondrial myopathies, Primary	Small molecules	Peroxisome proliferation activated receptor (PPAR) delta	PPAR modulator	Mono	-
10	Musculoskeletal	Phase 2	AT132		resamirigene bilparvovec	Myotubular myopathy, X-linked	Gene therapy	Myotubularin 1 (MTM1)	AAV-based gene therapy	Mono	-
11	Musculoskeletal	Phase 1	ASP0367		bocidelpar	Duchenne muscular dystrophy	Small molecules	Peroxisome proliferation activated receptor (PPAR) delta	PPAR modulator	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
11	Musculoskeletal	Phase 1	ASP0367		bocidelpar	Duchenne muscular dystrophy	Small molecules	Peroxisome proliferation activated receptor (PPAR) delta	PPAR modulator	Mono	-
12	Neuroscience	Phase 1	ASP8062			Alcohol use disorder	Small molecules	GABA B receptor	GABA B receptor modulator	Mono	-
13	Oncology	Phase3	ASG-22ME	Padcev+pembrolizumab	enfortumab vedotin+pembrolizumab	Bladder cancer, muscle-invasive	ADC	Nectin-4(PRR4)	Cytotoxic to cells expressing PRR4	Combination	Seagen
14	Oncology	Phase3	ASP2215	Xospata	gilteritinib	Acute myeloid leukemia, post-chemotherapy maintenance	Small molecules	FMS-like tyrosine kinase 3(FLT3)	FLT3 inhibitor	Mono	-
15	Oncology	Phase3	ASP2215	Xospata	gilteritinib	Acute myeloid leukemia, post-hematopoietic stem cell transplant maintenance	Small molecules	FMS-like tyrosine kinase 3(FLT3)	FLT3 inhibitor	Mono	-
16	Oncology	Phase3	ASP2215	Xospata	gilteritinib	Acute myeloid leukemia, newly diagnosed, with high intensity in duction of chemotherapy	Small molecules	FMS-like tyrosine kinase 3(FLT3)	FLT3 inhibitor	Mono	-
17	Oncology	Phase3	ASP2215	Xospata	gilteritinib	Acute myeloid leukemia, Pediatrics	Small molecules	FMS-like tyrosine kinase 3(FLT3)	FLT3 inhibitor	Mono	-
18	Oncology	Phase3	IMAB362		zolbetuximab	Adenocarcinoma, gastric and gastroesophageal junction	Antibody	Claudin 18 (CLDN18)	Cytotoxic to cells expressing CLDN18	Mono	-
19	Oncology	Phase 3	ASG-22ME	Padcev+pembrolizumab	enfortumab vedotin+pembrolizumab	Urothelial cancer, metastatic previously untreated, 1L	ADC	Nectin-4(PRR4)	Cytotoxic to cells expressing PRR4	Combination	Seagen
20	Oncology	Phase 3	MDV3100	Xtandi	enzalutamide	Prostate cancer, metastatic castration-sensitive	Small molecules	Androgen receptor	Androgen receptor Antagonist	Mono	Pfizer

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
21	Oncology	Phase 3	MDV3100	Xtandi	enzalutamide	Prostate cancer, non-metastatic castration-sensitive	Small molecules	Androgen receptor	Androgen receptor Antagonist	Mono	Pfizer
22	Oncology	Phase 2	ASG-22ME	Padcev	enfortumab Vedotin	Solid tumors	ADC	Nectin-4(PRR4)	Cytotoxic to cells expressing PRR4	Mono	Seagen
23	Oncology	Phase 2	IMAB362		zolbetuximab	Adenocarcinoma, pancreatic	Antibody	Claudin 18(CLDN18)	Cytotoxic to cells expressing CLDN18	Mono	-
24	Oncology	Phase 1	ASG-22ME	Padcev	enfortumab vedotin	Bladder cancer, non-muscle-invasive	ADC	Nectin-4(PRR4)	Cytotoxic to cells expressing PRR4	Mono	Seagen
25	Oncology	Phase 1	ASP0739			Cancer	Cell therapy	NY-ESO-1	Artificial adjuvant vector cells	Mono	RIKEN
26	Oncology	Phase 1	ASP1570			Cancer	Small molecules	Diacylglycerol kinase zeta(DGKZ)	DGKZ inhibitor	Mono	-
27	Oncology	Phase 1	ASP2138			Adenocarcinoma, gastric and gastroesophageal junction & pancreatic	Antibody	CD3, Claudin 6(CLDN6), Claudin 18(CLDN18)	Bispecific antibody (CD3, CLDN6, CLDN18)	Mono	Xencor
28	Oncology	Phase 1	ASP2215	Xospata	gilteritinib	Acute myeloid leukemia, newly diagnosed, with low intensity induction of chemotherapy	Small molecules	FMS-like tyrosine kinase 3(FLT3)	FLT3 inhibitor	Mono	-
29	Oncology	Phase 1	ASP3082			Cancer	Small molecules	KRAS G12D	KRAS G12D degrader	Mono	-
30	Oncology	Phase 2	IMAB362		zolbetuximab	Adenocarcinoma, pancreatic	Antibody	Claudin 18(CLDN18)	Cytotoxic to cells expressing CLDN18	Mono	-
31	Oncology	Phase 1	ASP7517			Solid tumors	Cell therapy	Wilms tumor 1(WT1)	artificial adjuvant vector cells	Mono	RIKEN

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
32	Oncology	Phase 1	ASP9801			Cancer	Virus	IL-7, IL-12	Oncolytic virus	Mono	Tottori University
33	Ophthalmology	Phase 1	ASP7317			Macular degeneration, geographic atrophy secondary, stargardt disease	Cell therapy	N/A	N/A	Mono	-
34	Others	Phase 2	FX-322			Hearing loss, sensorineural	Small molecules	GSK3, HDAC	GSK3/HDAC inhibitor	Mono	Frequency Therapeutics
35	Others	Phase 1	ASP0398			Tympanic membrane perforation, chronic	Protein	N/A	N/A	Mono	Auration Biotech